

Matthias P Wymann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8784018/publications.pdf>

Version: 2024-02-01

135
papers

14,933
citations

24978

57
h-index

18606

119
g-index

145
all docs

145
docs citations

145
times ranked

15417
citing authors

#	ARTICLE	IF	CITATIONS
1	Covalent Proximity Scanning of a Distal Cysteine to Target PI3K $\hat{1}$. Journal of the American Chemical Society, 2022, 144, 6326-6342.	6.6	27
2	The role of PI3K $\hat{3}$ in the immune system: new insights and translational implications. Nature Reviews Immunology, 2022, 22, 687-700.	10.6	22
3	Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood \hat{e} brain barrier permeability. RSC Medicinal Chemistry, 2021, 12, 579-583.	1.7	6
4	Disease-related mutations in PI3K $\hat{3}$ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. ELife, 2021, 10, .	2.8	28
5	Chemical and Structural Strategies to Selectively Target mTOR Kinase. ChemMedChem, 2021, 16, 2744-2759.	1.6	12
6	Suppression of caspase 8 activity by a coronin 1 \hat{e} PI3K $\hat{1}$ pathway promotes T cell survival independently of TCR and IL-7 signaling. Science Signaling, 2021, 14, eabj0057.	1.6	2
7	Targeting Phosphoinositide 3-Kinase \hat{e} Five Decades of Chemical Space Exploration. Chimia, 2021, 75, 1037.	0.3	3
8	Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. Neuropharmacology, 2020, 162, 107812.	2.0	12
9	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology, 2020, 180, 108297.	2.0	23
10	PI3K $\hat{3}$ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition \hat{e} Moving Towards Cell Specific PI3K Targeting?. Frontiers in Immunology, 2020, 11, 585070.	2.2	10
11	4-(Difluoromethyl)-5-(4-((3 <i>R</i>)-5 <i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. Journal of Medicinal Chemistry, 2020, 63, 13595-13617.	2.9	17
12	Abstract 665: Discovery and preclinical characterization of PQR626: A potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of tuberous sclerosis complex. , 2020, , .		0
13	A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. Journal of Medicinal Chemistry, 2019, 62, 8609-8630.	2.9	24
14	Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl \hat{e} Pyrimidine Moiety. ACS Medicinal Chemistry Letters, 2019, 10, 1473-1479.	1.3	28
15	Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. Organic Process Research and Development, 2019, 23, 2416-2424.	1.3	8
16	Human PI3K $\hat{3}$ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nature Communications, 2019, 10, 4364.	5.8	51
17	(<i>S</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. Journal of Medicinal Chemistry, 2019, 62, 6241-6261.	2.9	45
18	The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. Cancers, 2019, 11, 775.	1.7	14

#	ARTICLE	IF	CITATIONS
19	New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , 2019, 104, e256-e259.	1.7	43
20	A class of highly selective inhibitors bind to an active state of PI3K β . <i>Nature Chemical Biology</i> , 2019, 15, 348-357.	3.9	42
21	PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 120-129.	3.2	92
22	Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10084-10105.	2.9	62
23	The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. <i>Neuropharmacology</i> , 2018, 140, 107-120.	2.0	64
24	Deconvolution of Buparlisib β 's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention. <i>Nature Communications</i> , 2017, 8, 14683.	5.8	88
25	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7524-7538.	2.9	109
26	PI3K β activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. <i>Science Signaling</i> , 2017, 10, .	1.6	29
27	Abstract 153: Tricyclic fused pyrimidinopyrrolo-oxazines reveal conformational preferences of morpholine for PI3K hinge region binding. , 2017, , .		0
28	Abstract 140: Discovery and biological evaluation of PQR530, a highly potent dual pan-PI3K/mTORC1/2 inhibitor. , 2017, , .		1
29	Abstract 159: Pharmacological characterization of the selective, orally bioavailable, potent dual PI3K/mTORC1/2 inhibitor PQR530. , 2017, , .		1
30	Central role for phosphoinositide-3-kinase gamma/delta dependent signalling in eosinophilic pulmonary inflammation driven by innate lymphoid cells. , 2017, , .		0
31	Vascular remodeling in Cardiovascular Disease ²³¹ Absence of PI3K γ leads to increased reendothelialization in mice through modulation of IP-10 secretion. ²³² DPP4 inhibition mediates vascular protection in acute and chronic vascular injury ²³³ Effects of transforming growth factor beta signalling on smooth muscle cell phenotype in the angiotensin II-induced abdominal aortic aneurysm model. <i>Cardiovascular Research</i> , 2016, 111, S44-S44.	1.8	0
32	Abstract 393A: Pharmacological characterization of the selective, orally bioavailable, potent mTORC1/2 inhibitor PQR620. , 2016, , .		0
33	Abstract 1364: Novel 4-(pyrimidin-2-yl)morpholines targeting the colchicine-binding site of tubulin. , 2016, , .		0
34	Abstract 1336: Structure-activity relationship studies, synthesis, and biological evaluation of PQR620, a highly potent and selective mTORC1/2 inhibitor. , 2016, , .		0
35	0377 : Phosphoinositide 3-kinase gamma: a potential clinical target in the prevention of vascular damages inuced by arterial injury. <i>Archives of Cardiovascular Diseases Supplements</i> , 2015, 7, 134.	0.0	0
36	Abstract 2652: Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
37	Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor. <i>Cancer Research</i> , 2015, 75, 2664-2664.	0.4	3
38	Abstract 4514: PQR309: A potent, brain-penetrant, dual pan-PI3K/mTOR inhibitor with excellent oral bioavailability and tolerability. <i>Cancer Research</i> , 2015, 75, 4514-4514.	0.4	3
39	Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition. , 2015, , .		1
40	Elastin-derived peptides potentiate atherosclerosis through the immune Neu1-PI3K pathway. <i>Cardiovascular Research</i> , 2014, 102, 118-127.	1.8	91
41	Targeting PI3K activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. <i>Journal of Experimental Medicine</i> , 2014, 211, 1779-1792.	4.2	28
42	Cell-Permeant and Photocleavable Chemical Inducer of Dimerization. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 4717-4720.	7.2	51
43	Phosphoinositide 3-kinase \hat{I}^3 mediates microglial phagocytosis via lipid kinase-independent control of cAMP. <i>Neuroscience</i> , 2013, 233, 44-53.	1.1	30
44	Chemical Development of Intracellular Protein Heterodimerizers. <i>Chemistry and Biology</i> , 2013, 20, 549-557.	6.2	49
45	Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells' route to allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 959-968.	1.5	29
46	Membrane dynamics in physiology and disease. <i>FEBS Journal</i> , 2013, 280, 2729-2729.	2.2	1
47	Inhibition of phosphoinositide 3-kinase \hat{I}^3 attenuates inflammation, obesity, and cardiovascular risk factors. <i>Annals of the New York Academy of Sciences</i> , 2013, 1280, 44-47.	1.8	21
48	PKC \hat{I}^2 Phosphorylates PI3K \hat{I}^3 to Activate It and Release It from GPCR Control. <i>PLoS Biology</i> , 2013, 11, e1001587.	2.6	62
49	PI3K p110 \hat{I}^3 Deletion Attenuates Murine Atherosclerosis by Reducing Macrophage Proliferation but Not Polarization or Apoptosis in Lesions. <i>PLoS ONE</i> , 2013, 8, e72674.	1.1	17
50	Fluid-Phase Pinocytosis of Native Low Density Lipoprotein Promotes Murine M-CSF Differentiated Macrophage Foam Cell Formation. <i>PLoS ONE</i> , 2013, 8, e58054.	1.1	42
51	PI3Ks "Drug Targets in Inflammation and Cancer. <i>Sub-Cellular Biochemistry</i> , 2012, 58, 111-181.	1.0	9
52	Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3K \hat{I}^3 -dependent fluid-phase pinocytosis of native LDL. <i>Journal of Lipid Research</i> , 2012, 53, 34-42.	2.0	39
53	C-C motif chemokine CCL3 and canonical neutrophil attractants promote neutrophil extravasation through common and distinct mechanisms. <i>Blood</i> , 2012, 120, 880-890.	0.6	52
54	Genetic ablation of PI3K \hat{I}^3 results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. <i>European Journal of Immunology</i> , 2012, 42, 3394-3404.	1.6	14

#	ARTICLE	IF	CITATIONS
55	Key role of PI3K β in monocyte chemotactic protein α -mediated amplification of PDGF α -induced aortic smooth muscle cell migration. <i>British Journal of Pharmacology</i> , 2012, 166, 1643-1653.	2.7	29
56	The Chemical Biology of Phosphoinositide 3-Kinases. <i>ChemBioChem</i> , 2012, 13, 2022-2035.	1.3	35
57	Luminal decoration of blood vessels by activated perivascular mast cells in allergic rhinitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 510-520.	2.7	2
58	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110 β . <i>Molecular Cell</i> , 2011, 42, 84-95.	4.5	174
59	Neutral not a loss: phosphoinositides beyond the head group. <i>Nature Methods</i> , 2011, 8, 219-220.	9.0	3
60	PI3K β within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E854-63.	3.3	55
61	Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Posts ischemic Microvasculature. <i>PLoS ONE</i> , 2011, 6, e17229.	1.1	54
62	Targeting PI3K in neuroblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 1881-1890.	1.2	19
63	Essential Role of the p110 β Subunit of Phosphoinositide 3-OH Kinase in Male Fertility. <i>Molecular Biology of the Cell</i> , 2010, 21, 704-711.	0.9	58
64	Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors. <i>Molecular Cancer Research</i> , 2009, 7, 601-613.	1.5	105
65	Ras is an indispensable coregulator of the class I β phosphoinositide 3-kinase p87/p110 β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20312-20317.	3.3	84
66	Leukocyte transmigration is modulated by chemokine-mediated PI3K β -dependent phosphorylation of vimentin. <i>European Journal of Immunology</i> , 2009, 39, 1136-1146.	1.6	59
67	Essential role of phosphoinositide 3-kinase γ in eosinophil chemotaxis within acute pulmonary inflammation. <i>Immunology</i> , 2009, 126, 413-422.	2.0	33
68	Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. <i>EMBO Journal</i> , 2009, 28, 2018-2027.	3.5	103
69	Mast cell degranulation requires activation of PI3K β by PKC δ . <i>Cytokine</i> , 2009, 48, 41.	1.4	0
70	PI3K β Adaptor Subunits Define Coupling to Degranulation and Cell Motility by Distinct PtdIns(3,4,5)P $_3$ Pools in Mast Cells. <i>Science Signaling</i> , 2009, 2, ra27.	1.6	80
71	Targeting phosphoinositide 3-kinase—Moving towards therapy. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2008, 1784, 159-185.	1.1	491
72	Lipid signalling in disease. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 162-176.	16.1	1,091

#	ARTICLE	IF	CITATIONS
73	The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression. <i>Molecular and Cellular Biology</i> , 2008, 28, 5886-5898.	1.1	150
74	Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase- \hat{I}^3 Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes. <i>Circulation</i> , 2008, 117, 1310-1317.	1.6	131
75	Phosphoinositide 3-Kinase p110 \hat{I}^2 Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. <i>Science Signaling</i> , 2008, 1, ra3.	1.6	219
76	Phosphoinositide 3-kinase gamma; participates in T cell receptor-induced T cell activation.. <i>FASEB Journal</i> , 2008, 22, 1064.12.	0.2	4
77	A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphate-mediated egress. <i>Journal of Experimental Medicine</i> , 2007, 204, 497-510.	4.2	144
78	Phosphoinositide 3-kinase \hat{I}^3 participates in T cell receptor-induced T cell activation. <i>Journal of Experimental Medicine</i> , 2007, 204, 2977-2987.	4.2	86
79	Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase \hat{I}^3 . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 14354-14359.	3.3	57
80	Inactivation of PI3K \hat{I}^3 and PI3K \hat{I}^r distorts T-cell development and causes multiple organ inflammation. <i>Blood</i> , 2007, 110, 2940-2947.	0.6	113
81	GABAA receptor-associated phosphoinositide 3-kinase is required for insulin-induced recruitment of postsynaptic GABAA receptors. <i>Neuropharmacology</i> , 2007, 52, 146-155.	2.0	44
82	PI(3)K \hat{I}^3 has an important context-dependent role in neutrophil chemokinesis. <i>Nature Cell Biology</i> , 2007, 9, 86-91.	4.6	233
83	Phosphoinositide 3-kinase \hat{I}^3 participates in T cell receptor-induced T cell activation. <i>Journal of Cell Biology</i> , 2007, 179, i9-i9.	2.3	0
84	Lack of phosphoinositide 3-kinase- \hat{I}^3 attenuates ventilator-induced lung injury*. <i>Critical Care Medicine</i> , 2006, 34, 134-141.	0.4	62
85	Class IB-Phosphatidylinositol 3-Kinase (PI3K) Deficiency Ameliorates IA-PI3K-Induced Systemic Lupus but Not T Cell Invasion. <i>Journal of Immunology</i> , 2006, 176, 589-593.	0.4	78
86	Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. <i>Blood</i> , 2005, 106, 1432-1440.	0.6	274
87	Blockade of PI3K \hat{I}^3 suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. <i>Nature Medicine</i> , 2005, 11, 936-943.	15.2	711
88	Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. <i>Current Opinion in Cell Biology</i> , 2005, 17, 141-149.	2.6	198
89	Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. <i>European Journal of Immunology</i> , 2005, 35, 1283-1291.	1.6	70
90	Cutting Edge: T Cell Development Requires the Combined Activities of the p110 \hat{I}^3 and p110 \hat{I}^r Catalytic Isoforms of Phosphatidylinositol 3-Kinase. <i>Journal of Immunology</i> , 2005, 175, 2783-2787.	0.4	142

#	ARTICLE	IF	CITATIONS
91	Susi, a Negative Regulator of Drosophila PI3-Kinase. <i>Developmental Cell</i> , 2005, 8, 817-827.	3.1	24
92	Phosphoinositide 3-kinase \hat{I}^3 controls autonomic regulation of the mouse heart through Gi-independent downregulation of cAMP level. <i>FEBS Letters</i> , 2005, 579, 133-140.	1.3	20
93	Defective dendritic cell migration and activation of adaptive immunity in PI3K \hat{I}^3 -deficient mice. <i>EMBO Journal</i> , 2004, 23, 3505-3515.	3.5	146
94	Phosphoinositide 3-kinase \hat{I}^3 mediates Jun kinase activation via its lipid-kinase activity. <i>Advances in Enzyme Regulation</i> , 2004, 44, 299-308.	2.9	1
95	PI3K \hat{I}^3 Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects. <i>Cell</i> , 2004, 118, 375-387.	13.5	446
96	The direct effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between de novo lipogenesis and lipid oxidation. <i>FEBS Letters</i> , 2004, 577, 539-544.	1.3	95
97	Ablation of Phosphoinositide 3-Kinase- \hat{I}^3 Reduces the Severity of Acute Pancreatitis. <i>American Journal of Pathology</i> , 2004, 165, 2003-2011.	1.9	49
98	Requirement for PI 3-kinase \hat{I}^3 in macrophage migration to MCP-1 and CSF-1. <i>Experimental Cell Research</i> , 2003, 290, 120-131.	1.2	94
99	Phosphoinositide 3-kinase signalling – which way to target?. <i>Trends in Pharmacological Sciences</i> , 2003, 24, 366-376.	4.0	374
100	Activation of PI3-Kinase Is Required for AMPA Receptor Insertion during LTP of mEPSCs in Cultured Hippocampal Neurons. <i>Neuron</i> , 2003, 38, 611-624.	3.8	317
101	A Selective Role for Phosphatidylinositol 3,4,5-Trisphosphate in the Gi-dependent Activation of Platelet Rap1B. <i>Journal of Biological Chemistry</i> , 2003, 278, 131-138.	1.6	92
102	Phosphatidylinositol 3-Kinase Regulates the CD4/CD8 T Cell Differentiation Ratio. <i>Journal of Immunology</i> , 2003, 170, 4475-4482.	0.4	79
103	Phosphoinositide 3-kinase \hat{I}^3 -deficient hearts are protected from the PAF-dependent depression of cardiac contractility. <i>Cardiovascular Research</i> , 2003, 60, 242-249.	1.8	20
104	Phosphoinositide 3-kinase \hat{I}^3 : a key modulator in inflammation and allergy. <i>Biochemical Society Transactions</i> , 2003, 31, 275-280.	1.6	125
105	Living with Lethal PIP3 Levels: Viability of Flies Lacking PTEN Restored by a PH Domain Mutation in Akt/PKB. <i>Science</i> , 2002, 295, 2088-2091.	6.0	190
106	Loss of phosphatase activity in myotubularin-related protein 2 is associated with Charcot-Marie-Tooth disease type 4B1. <i>Human Molecular Genetics</i> , 2002, 11, 1569-1579.	1.4	124
107	Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways. <i>Cell</i> , 2002, 110, 737-749.	13.5	545
108	Phosphoinositide 3-Kinase \hat{I}^3 Is an Essential Amplifier of Mast Cell Function. <i>Immunity</i> , 2002, 16, 441-451.	6.6	292

#	ARTICLE	IF	CITATIONS
109	Membrane transport in <i>Caenorhabditis elegans</i> : an essential role for VPS34 at the nuclear membrane. <i>EMBO Journal</i> , 2002, 21, 1673-1683.	3.5	80
110	The <i>Drosophila</i> insulin/IGF receptor controls growth and size by modulating PtdInsP ₃ levels. <i>Development (Cambridge)</i> , 2002, 129, 4103-4109.	1.2	142
111	The ATP-binding site of brain phosphatidylinositol 4-kinase PI4K230 as revealed by 5 ^α - ² -p-fluorosulfonylbenzoyladenine. <i>International Journal of Biochemistry and Cell Biology</i> , 2001, 33, 249-259.	1.2	11
112	Protein adsorption on topographically nanostructured titanium. <i>Surface Science</i> , 2001, 474, L180-L184.	0.8	62
113	Weakening link to colorectal cancer?. <i>Nature</i> , 2001, 413, 796-796.	13.7	41
114	Resistance to thromboembolism in PI3K ^Δ deficient mice. <i>FASEB Journal</i> , 2001, 15, 2019-2021.	0.2	201
115	Activation Loop Sequences Confer Substrate Specificity to Phosphoinositide 3-Kinase $\hat{\pm}$ (PI3K $\hat{\pm}$). <i>Journal of Biological Chemistry</i> , 2001, 276, 21544-21554.	1.6	86
116	Lipids on the move: phosphoinositide 3-kinases in leukocyte function. <i>Trends in Immunology</i> , 2000, 21, 260-264.	7.5	122
117	Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase, Rho, and Rac-dependent signaling pathways. <i>FASEB Journal</i> , 2000, 14, 2329-2338.	0.2	230
118	Analysis of the murine phosphoinositide 3-kinase $\hat{\pm}$ gene. <i>Gene</i> , 2000, 256, 69-81.	1.0	16
119	Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. <i>Molecular Cell</i> , 2000, 6, 909-919.	4.5	1,102
120	Central Role for G Protein-Coupled Phosphoinositide 3-Kinase in Inflammation. <i>Science</i> , 2000, 287, 1049-1053.	6.0	1,187
121	Phosphoinositide 3-kinase Signalling – no lipids. <i>Biochemical Society Transactions</i> , 1999, 27, A74-A74.	1.6	0
122	Microquantification of Cellular and in Vitro F-Actin by Rhodamine Phalloidin Fluorescence Enhancement. <i>Analytical Biochemistry</i> , 1998, 264, 185-190.	1.1	19
123	Structure and function of phosphoinositide 3-kinases. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 1998, 1436, 127-150.	1.2	582
124	Bifurcation of Lipid and Protein Kinase Signals of PI3K to the Protein Kinases PKB and MAPK. , 1998, 282, 293-296.		288
125	The Ras/Rac1/Cdc42/SEK/JNK/c-Jun Cascade Is a Key Pathway by Which Agonists Stimulate DNA Synthesis in Primary Cultures of Rat Hepatocytes. <i>Molecular Biology of the Cell</i> , 1998, 9, 561-573.	0.9	127
126	Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase $\hat{\pm}$: structure-activity analysis and interactions with wortmannin. <i>Biochemical Journal</i> , 1997, 324, 489-495.	1.7	100

#	ARTICLE	IF	CITATIONS
127	Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4960-4964.	3.3	201
128	N-formyl peptide receptors in human neutrophils display distinct membrane distribution and lateral mobility when labeled with agonist and antagonist.. Journal of Cell Biology, 1993, 121, 1281-1289.	2.3	46
129	Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils.. Journal of Clinical Investigation, 1991, 87, 2012-2017.	3.9	106
130	Turning on the respiratory burst. Trends in Biochemical Sciences, 1990, 15, 69-72.	3.7	197
131	Respiratory burst oscillations in human neutrophils and their correlation with fluctuations in apparent cell shape. Journal of Biological Chemistry, 1989, 264, 15829-34.	1.6	51
132	Increased breakdown of phosphatidylinositol 4,5-bisphosphate is not an initiating factor for actin assembly in human neutrophils. Journal of Biological Chemistry, 1988, 263, 17385-9.	1.6	44
133	Oscillatory motion in human neutrophils responding to chemotactic stimuli. Biochemical and Biophysical Research Communications, 1987, 147, 361-368.	1.0	27
134	Chemiluminescence detection of H ₂ O ₂ produced by human neutrophils during the respiratory burst. Analytical Biochemistry, 1987, 165, 371-378.	1.1	145
135	The onset of the respiratory burst in human neutrophils. Real-time studies of H ₂ O ₂ formation reveal a rapid agonist-induced transduction process. Journal of Biological Chemistry, 1987, 262, 12048-53.	1.6	76